Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Ravi Visswanathan"'
Autor:
Paolo Vicini, Erica L. Bradshaw-Pierce, Judy Lucas, Gang Li, Shinji Yamazaki, Chandra Vage, Ravi Visswanathan, Xiaoying Chen, Mary E. Spilker
Trastuzumab CRD Calculation Details
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6432acf19612f1e3aef15c601f41b2f
https://doi.org/10.1158/1078-0432.22466916.v1
https://doi.org/10.1158/1078-0432.22466916.v1
Autor:
Paolo Vicini, Erica L. Bradshaw-Pierce, Judy Lucas, Gang Li, Shinji Yamazaki, Chandra Vage, Ravi Visswanathan, Xiaoying Chen, Mary E. Spilker
Description of common pharmacokinetic parameters used in the CRD calculations.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4448f1b2e533650c26b835eddec72a09
https://doi.org/10.1158/1078-0432.22466919.v1
https://doi.org/10.1158/1078-0432.22466919.v1
Autor:
Paolo Vicini, Erica L. Bradshaw-Pierce, Judy Lucas, Gang Li, Shinji Yamazaki, Chandra Vage, Ravi Visswanathan, Xiaoying Chen, Mary E. Spilker
Dasatinib CRD Calculation Details
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ba03f7ddef0141746657d3d973194d4
https://doi.org/10.1158/1078-0432.22466925.v1
https://doi.org/10.1158/1078-0432.22466925.v1
Autor:
Paolo Vicini, Erica L. Bradshaw-Pierce, Judy Lucas, Gang Li, Shinji Yamazaki, Chandra Vage, Ravi Visswanathan, Xiaoying Chen, Mary E. Spilker
Vismodegib CRD Calculation Details
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa49ae495587c32c40c82b321820aa77
https://doi.org/10.1158/1078-0432.22466913
https://doi.org/10.1158/1078-0432.22466913
Autor:
Paolo Vicini, Erica L. Bradshaw-Pierce, Judy Lucas, Gang Li, Shinji Yamazaki, Chandra Vage, Ravi Visswanathan, Xiaoying Chen, Mary E. Spilker
Purpose: The translation of nonclinical oncology studies is a subject of continuous debate. We propose that translational oncology studies need to optimize both pharmacokinetic (drug exposure) and pharmacodynamic (xenograft model) aspects. While impr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49f3b5251c6cb1f7d159009e3d3a9100
https://doi.org/10.1158/1078-0432.c.6526479.v1
https://doi.org/10.1158/1078-0432.c.6526479.v1
Autor:
Paolo Vicini, Erica L. Bradshaw-Pierce, Judy Lucas, Gang Li, Shinji Yamazaki, Chandra Vage, Ravi Visswanathan, Xiaoying Chen, Mary E. Spilker
Full Description with references for the data included in Figure 4.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4150efa684d74c6679f80a41d19a9ac1
https://doi.org/10.1158/1078-0432.22466922.v1
https://doi.org/10.1158/1078-0432.22466922.v1
Autor:
Kephart Susan Elizabeth, Tran Khanh Tuan, Kevin Daniel Freeman-Cook, Sherry Niessen, James Solowiej, Buwen Huang, Qin Zhang, Douglas Carl Behenna, Inish O'Doherty, Sacha Ninkovic, Rose Ann Ferre, Andrea Hui, Nichol Miller, Jordan Carelli, Lisa Nguyen, Brion W. Murray, Robert Louis Hoffman, John Lapek, Rhys M. Jones, Meirong Xu, Stephen Dann, Sutton Scott Channing, Asako Nagata, Nanni Huser, Ravi Visswanathan, Zehnder Luke Raymond, Elaine E. Tseng, Britton Boras, You-Ai He, Michele McTigue, Wade Diehl, Cathy Zhang, Martha A. Ornelas
Publikováno v:
Journal of medicinal chemistry. 64(13)
Control of the cell cycle through selective pharmacological inhibition of CDK4/6 has proven beneficial in the treatment of breast cancer. Extending this level of control to additional cell cycle CDK isoforms represents an opportunity to expand to add
Autor:
Meirong Xu, Koleen Eisele, Douglas Carl Behenna, John Chionis, Sutton Scott Channing, Cathy Zhang, Ping Wei, Ravi Visswanathan, Stephen Dann, B Jessen, Robert M. Hoffman, Britton Boras, Kevin Daniel Freeman-Cook, Michael A. White, Qin Zhang, Brion W. Murray, Jing Yuan, Sacha Ninkovic, Scott L. Weinrich, Nanni Huser, Jim Solowiej, Nichol Miller, Todd VanArsdale, Chaoting Liu
Publikováno v:
Cancer Research. 79:P6-20
This abstract was withdrawn by the authors. Citation Format: Dann S, Chionis J, Eisele K, Zhang Q, Liu C, Yuan J, Miller N, Murray B, Xu M, Solowiej J, Wei P, Weinrich S, Sutton S, Behenna D, Ninkovic S, Hoffman R, Freeman-Cook K, Jessen B, Huser N,
Autor:
Xinmeng Jasmine Mu, Meirong Xu, Shahram Salek-Ardakani, Cinthia Costa-Jones, Lisa Nguyen, James Solowiej, David Looper, Scott L. Weinrich, Robert Louis Hoffman, Sutton Scott Channing, Sacha Ninkovic, Kephart Susan Elizabeth, Sherry Niessen, John Chionis, Jadwiga Bienkowska, Kevin Daniel Freeman-Cook, Rose Ann Ferre, John Lapek, Cecilia Oderup, Jordan Carelli, Cathy Zhang, Nanni Huser, Elizabeth A. McMillan, Asako Nagata, Martha A. Ornelas, Brion W. Murray, Douglas Carl Behenna, Koleen Eisele, Todd VanArsdale, Zhou Zhu, Zhengyan Kan, Chaoting Liu, Nichol Miller, Zehnder Luke Raymond, Michael A. White, Ying Ding, Nathan V. Lee, Jonathan Almaden, Qin Zhang, Tran Khanh Tuan, Ping Wei, Stephen Dann, Britton Boras, Tim S. Wang, Ravi Visswanathan, You-Ai He, Michele McTigue, Elizabeth Wilson
Publikováno v:
Cancer Cell. 39:1404-1421.e11
Summary The CDK4/6 inhibitor, palbociclib (PAL), significantly improves progression-free survival in HR+/HER2− breast cancer when combined with anti-hormonals. We sought to discover PAL resistance mechanisms in preclinical models and through analys
Autor:
James P. Saunders, Christopher L Holliman, Wei Song, Joseph A Tweed, Zhenhua Gu, Ravi Visswanathan
Publikováno v:
Analytical chemistry. 91(21)
This work represents the first reporting of a comprehensive bioanalytical GLP methodology detailing the mass spectrometric quantitation of PF-05212384 dosed as a targeted polymeric encapsulated nanoparticle (PF-07034663) to monkeys. Polymeric nanopar